SOPHiA Genetics SA [SOPH] stock prices are up 2.49% to $4.93 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The SOPH shares have gain 22.94% over the last week, with a monthly amount glided 20.54%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
SOPHiA Genetics SA [NASDAQ: SOPH] stock has seen the most recent analyst activity on December 18, 2024, when Craig Hallum initiated its Buy rating and assigned the stock a price target of $11. Previously, Morgan Stanley downgraded its rating to Equal-Weight on August 07, 2024, and dropped its price target to $5. On June 27, 2024, Guggenheim initiated with a Buy rating and assigned a price target of $6 on the stock. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $8 on November 29, 2023. BTIG Research started tracking with a Buy rating for this stock on January 03, 2023, and assigned it a price target of $6. In a note dated November 23, 2022, Credit Suisse initiated an Neutral rating and provided a target price of $2 on this stock.
The stock price of SOPHiA Genetics SA [SOPH] has been fluctuating between $2.58 and $5.30 over the past year. Currently, Wall Street analysts expect the stock to reach $5.33 within the next 12 months. SOPHiA Genetics SA [NASDAQ: SOPH] shares were valued at $4.93 at the most recent close of the market. An investor can expect a potential return of 8.11% based on the average SOPH price forecast.
Analyzing the SOPH fundamentals
The SOPHiA Genetics SA [NASDAQ:SOPH] reported sales of 73.30M for trailing twelve months, representing a surge of 22.77% . Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at -0.97%, Pretax Profit Margin comes in at -1.02%, and Net Profit Margin reading is -1.05%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -0.79 and Total Capital is -0.47. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.83.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.81 points at the first support level, and at 4.70 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.00, and for the 2nd resistance point, it is at 5.07.
Ratios To Look Out For
It’s worth pointing out that SOPHiA Genetics SA [NASDAQ:SOPH]’s Current Ratio is 2.80. On the other hand, the Quick Ratio is 2.62, and the Cash Ratio is 2.75. Considering the valuation of this stock, the price to sales ratio is 4.55, the price to book ratio is 5.51.
Transactions by insiders
Recent insider trading involved JURGI CAMBLONG, Director, that happened on Nov 10 ’25 when 24641.0 shares were purchased. Director, KATHY L HIBBS completed a deal on Nov 03 ’25 to buy 10000.0 shares. Meanwhile, Officer PHILIPPE MENU bought 1628.0 shares on Oct 30 ’25.
